Amuvatinib MP 470 Cas 850879-09-3 Bioavailable Synthetic Carbothioamide
Amuvatinib MP 470 Cas 850879-09-3 Bioavailable Synthetic Carbothioamide
+ AII PRODUCTS
- Prostaglandins - Custom Synthesis - PARP Inhibitors - PI3K Inhibitors - FAK Inhibitors - AKT Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - c-Met Inhibitors - CDK Inhibitors - CYP17 Inhibitors - DNA/RNA Inhibitors - mTOR Inhibitors - SRC Inhibitors - Others
Product
|
Size |
Price |
Stock |
Quantity |
|---|---|---|---|
|
Get Quotation Now Add to Cart Bulk Inquiry |
|||
Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.
Chemical Information
|
Product name:Amuvatinib MP-470 |
Purity:98% min |
|
CAS NO:850879-09-3 |
Solubility:DMSO50 mg/mL (111.73 mM) |
|
Molecular Formula:C23H21N5O3S |
Package:Package according to customer requirements |
|
Molecular Weight:447.51 |
Storage:Store at -20℃ |
Quality control
Remarks
Amuvatinib, also known as MP-470, is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity. Multitargeted receptor tyrosine kinase inhibitor MP470 binds to mutant forms of the stem cell factor receptor (c-Kit; SCFR), inhibiting clinically relevant mutants of this receptor tyrosine kinase that may be associated with resistance to therapy. In addition, MP470 inhibits activities of other receptor tyrosine kinases, such as c-Met, Ret oncoprotein, and mutant forms of Flt3 and PDGFR alpha, which are frequently dysregulated in variety of tumors.
Related Products
Pexidartinib hcl; Pexidartinib; Telatinib; Avapritinib; DovitinibLactate; Linifanib; OSI-930; Crenolanib; Motesanib Diphosphate; Motesanib; Sunitinib; Imatinib mesylate; Axitinib; Masitinib; Dovitinib; ISCK03
References
[1].Bearss DJ, et al. US Patent, US/2008/0226747.
[2].Hurley LH, et al. World Patent, WO/2005/037825.
[3].Mahadevan D, et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene, 2007, 26(27), 3909-3919.
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.